Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. Eduardo Alegria-Ezquerra
Mr Eduardo Alegria-Barrero
Sodium restriction is frequently recommended by doctors and neglected by patients. One possible method to increase adherence to salt restriction is to objectively demonstrate quantity of daily salt intake. Considerations regarding the practical utility of this method are described.
Sodium restriction is one of the most frequently prescribed lifestyle measures taken in everyday clinical activity. However, as frequently as this easy and effective preventative therapy is recommended by doctors, as often it is neglected by patients. One possible way to increase adherence to salt restriction – mainly for patients insisting that they actually do so- would be to objectively demonstrate how large their daily salt intake actually is. To that end, urinary sodium content measurement seems to be the preferred method. Considerations regarding the practical utility of this method from the point of view of a practical cardiologist will follow. Key Points:
Evidence relating salt intake and cardiovascular health and disease come from numerous animal experiments, epidemiological studies, dietary trials, and clinical observations.(1) Dietary sodium content is directly related not only with blood pressure (INTERSALT Study), but also with total mortality (NHANES 1988-2006), coronary risk (CARDIA Study), heart failure outcomes (2) and other cardiovascular outcomes, despite a recent controversy related mainly to patients with advanced heart failure. (3, 4)
Unfavorable high sodium intakes remain prevalent around the world (INTERMAP Study). (5) Sources of dietary sodium come from processed foods, table salt voluntarily added and in some cases soluble over-the-counter drugs (Fig.1). Figure 1 International guidelines on nutrition unanimously recommend sodium restriction, ideally to less than 5 g/day.(6) It is estimated that decreasing dietary intake from 10 grams to 5 grams per day would reduce the overall stroke rate by 23% and cardiovascular disease rates by 17%.(7) Thus, a number of scientific organisations and some countries have accepted this challenge and have implemented some strategies in that direction at the community level, by means of affordable and cost-effective public health interventions (involving multi-stakeholders, from family doctors to food manufacturers or restaurant industries). For example, the American Heart Association has launched the improvement of cardiovascular health of all Americans by 20% as one of its goals for the year 2020; two parameters included in the “ideal cardiovascular health” are a blood pressure of less than 120/80 mm Hg and a sodium consumption of less than 1500 mg/day (1,5 grams).
But we as doctors have to deal with individual patients and have the responsibility of guaranteeing that our patients who would benefit from sodium restriction (most of them) or have a compulsory indication for that (heart failure, hypertension) actually manage to comply with it. A useless way to achieve that goal is general advice “try to use as less salt as possible” briefly offered among other dietary recommendations, allowing more time and giving more importance to prescribing drugs. On the contrary, as important this objective is, salt restriction needs a greater effort and a continuing support in order to be achieved. (8)
One of the tools which could help to succeed in reducing salt intake by individuals is to measure directly how much salt (sodium) they eat, and to use this information to reinforce the necessity of reducing it. Self-reported food consumption in questionnaires or surveys is usually inaccurate. Measuring the 24-hour urinary sodium excretion is the reference method, but has been used up to now almost exclusively as a research tool. Why not apply this method to clinical needs? The main reason not to has probably been the perceived complexity of collecting urine in the course of one day. Other drawbacks are the need to assure that all 24-hour urine has been adequately and completely collected (detailed instructions, excretion of para-aminobenzoic taken simultaneously by mouth or creatinine excretion in relation to body weight), the underestimation or true sodium intake by a 10-15% (due to electrolyte loss by skin and lungs), and the interindividual variability of sodium excretion. For clinical purposes, it is possible to simplify the technique by measuring sodium excretion only once in a single morning urine sample simultaneously with creatinine and total daily urine volume (measured or inferred). Daily salt intake based on 24-hour urinary sodium excretion (assuming that all sodium ingested was in the form of sodium chloride) with a formula: figure 2 shows a practical method to estimate salt or sodium intake. Figure 2: Calculation for estimation of salt or sodium intake Na (mg/day) = Na (mmol/day) x 23; NaCl = Na (g/day) x 100/ 39,3 1 gram salt (NaCl) = 393,4 mg Na = 17,1 mmol Na
This method to quantify sodium intake, although simple, easy and inexpensive, is probably not worth applying to the whole cohort of cardiologist’s outpatients. But perhaps it could help in the management of some cases, summarised as follows:
1.Susic D, Frohlich ED. Salt consumption and cardiovascular, renal, and hypertensive diseases: clinical and mechanistic aspects. Curr Opin Lipidol. 2012;23:11-6. 2.He FJ, Burnier M, MacGregor GA. Nutrition in cardiovascular disease: salt in hypertension and heart failure. Eur Heart J. 2011;32:3073-80. 3.O'Donnell MJ, Yusuf S, Mente A, Gao P, Mann JF, Teo K, et al. Urinary sodium and potassium excretion and risk of cardiovascular events. JAMA. 2011 Nov 23;306(20):2229-38. 4.Taylor RS, Ashton KE, Moxham T, Hooper L, Ebrahim S. Reduced dietary salt for the prevention of cardiovascular disease: a meta-analysis of randomized controlled trials (Cochrane review). Am J Hypertens. 2011;24:843-53. 5.Brown IJ, Tzoulaki I, Candeias V, Elliott P. Salt intakes around the world: implications for public health. Int J Epidemiol. 2009;38:791-813. 6.World Health Organization. Action plan for implementation of the European Strategy for the Prevention and Control of Noncommunicable Diseases 2012–2016. EUR/RC61/12. 7.Bibbins-Domingo K, Chertow GM, Coxson PG, Moran A, Lightwood JM, Pletcher MJ, Goldman L. Projected effect of dietary salt reductions on future cardiovascular disease. N Engl J Med. 2010;362:590-9. 8.Polonia J, Martins L. A comprehensive review on salt and health and current experience of worldwide salt reduction programmes. J Hum Hypertens. 2009;23:771-2. 9.Sullivan JM. Salt sensitivity. Definition, conception, methodology, and long-term issues. Hypertension. 1991;17(1 Suppl):I61-8. http://www.ncbi.nlm.nih.gov/pubmed/1987013 10.Lieb W, Pencina MJ, Jacques PF, Wang TJ, Larson MG, Levy D, et al. Higher aldosterone and lower N-terminal proatrial natriuretic peptide as biomarkers of salt sensitivity in the community. Eur J Cardiovasc Prev Rehabil. 2011;18:664-73.
Eduardo Alegría-Ezquerra1Eduardo Alegría-Barrero2Ana Alegría-Barrero31Cardiology Department. Policlínica Gipuzkoa. San Sebastián. Spain2Interventional Cardiology. Royal Brompton Hospital. London. UK3Cardiology Department. Montepríncipe Hospital. Madrid. SpainAuthors' disclosures: None declared.
© 2017 European Society of Cardiology. All rights reserved